Merck's Experimental HIV Prevention Pill Could Be Produced for Under $5 a Year, Researchers Say

A new analysis finds Merck's experimental HIV prevention pill could be manufactured for less than $5 a year per patient at generic scale. Global health advocates say the cost collapse could remake PrEP access in low- and middle-income countries. Merck has not yet committed to a pricing framework.